Retraction Notice: The Role of CD276 in Promoting Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Through DNA Damage Repair and FAK-MAPK Pathway Activation - Takeaways - MDSpire

Retraction Notice: The Role of CD276 in Promoting Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Through DNA Damage Repair and FAK-MAPK Pathway Activation

  • By

  • Zhi-yu Zhang

  • Jian-hao Xu

  • Jiang-lei Zhang

  • Yu-xin Lin

  • Jun Ou-Yang

  • January 12, 2026

  • 0 min

Share

  • 1

    The article titled 'The Role of CD276 in Promoting Sunitinib Resistance in Clear Cell Renal Cell Carcinoma' has been retracted.

  • 2

    The retraction was initiated after the corresponding author requested a correction for a duplicated image.

  • 3

    Further investigation revealed discrepancies in the western blot scans and expected molecular weights of proteins.

  • 4

    The authors failed to provide sufficient explanations and original raw data to address the discrepancies.

  • 5

    All authors have agreed to the retraction due to the lack of confidence in the presented data.

Original Source(s)

Retraction Notice: The Role of CD276 in Promoting Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Through DNA Damage Repair and FAK-MAPK Pathway Activation

  • by Zhi-yu Zhang, Jian-hao Xu, Jiang-lei Zhang, Yu-xin Lin, Jun Ou-Yang

  • January 12, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report